FDA APPROVES ZELBORAF AND COMPANION DIAGNOSTIC TEST FOR LATE-STAGE SKIN CANCER August 23, 2011 BRAF V600E +3 cobas 4800 BRAF V600 Mutation Test dacarbazine skin cancer Zelboraf (vemurafenib) BRAF V600E cobas 4800 BRAF V600 Mutation Test dacarbazine skin cancer Zelboraf (vemurafenib)
ADCETRIS TO TREAT TWO TYPES OF LYMPHOMA August 23, 2011 Adcetris CD30 FDA +1 Hodgkin lymphoma (HL) lymphoma cells NATIONAL CANCER INSTITUTE systemic anaplastic large cell lymphoma (ALCL) Adcetris CD30 FDA Hodgkin lymphoma (HL) lymphoma cells NATIONAL CANCER INSTITUTE systemic anaplastic large cell lymphoma (ALCL)
FDA ISSUES NEW GUIDELINES TO IMPROVE QUALITY OF CLINICAL TRIAL August 21, 2011 FDA +0 New guidelines FDA New guidelines
CARDIAC MYOSIN ACTIVATORS: A NEW CLASS OF DRUGS FOR HEART FAILURE TREATMENT August 21, 2011 cardiac myosin activators +1 heart failure treatment myosin Omecamtiv mercabil cardiac myosin activators heart failure treatment myosin Omecamtiv mercabil
PFIZER CONDUCTS FIRST “VIRTUAL” CLINICAL TRIAL August 06, 2011 FDA OAB Treatment Experience – REMOTE +1 overactive bladder PFIZER PFIZER CONDUCTS FIRST VIRTUAL CLINICAL TRIAL FDA OAB Treatment Experience – REMOTE overactive bladder PFIZER PFIZER CONDUCTS FIRST VIRTUAL CLINICAL TRIAL